Attorney Docket No.: 6133.214-US

Please add the following Abstract to the pending application:--

ABSTRACT

A system for assisting in blood glucose control of a human patient is disclosed. One aspect of the disclosure provides for a system that allows inputs of various parameters related to the patient and outputs a control signal containing information relating to how the patient may achieve a desired blood glucose level. The output signal may be transmitted directly to a device that administers an agent, such as insulin, to the patient. The signal may contain the requisite dosing information to achieve the desired result.

Attorney Docket No.: 6133.214-US

The commissioner is hereby authorized to charge \$470 for total additional claim fees for this application and any payments related to this application to Novo Nordisk's Deposit Account, No. 14-1447 and to credit any over payments to the same account. Should any petitions for extensions of time be required, applicants respectfully request such petitions and authorize payment of any fees due in connection with them to the above referenced deposit account.

Respectfully submitted,

Date: February 11, 2003

Marc A. Began, Reg. No. 48,829 Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton, NJ 08540

(609) 987-5800

23650 PATENT TRADEMARK OFFICE